### **ORIGINAL ARTICLE**

# Identifying the Phenotypes of Sepsis that will Benefit from Red Blood Cell Transfusion Using Unsupervised Cluster Analysis

Haojia Yu<sup>1</sup>, Hui Zhang<sup>1</sup>, Yue Lang<sup>1</sup>, Suwei Li<sup>2</sup>, Xianyao Wan<sup>2</sup>

<sup>1</sup> Department of Neurointensive Care Unit, The Second Affiliated Hospital of Dalian Medical University, Dalian City, Liaoning Province, China
<sup>2</sup> Department of Intensive Care Unit, The First Affiliated Hospital of Dalian Medical University, Dalian City, Liaoning Province, China

#### **SUMMARY**

Background: Sepsis is a heterogeneous syndrome. Previous studies have shown controversial results of the effects of red blood cell transfusion (RBC) on the clinical outcomes of septic patients. This study aimed to identify the phenotypes of sepsis that will benefit from RBC transfusion.

Methods: Clinical data were extracted from the Medical Information Mart for Intensive Care III database. The study population included adult (age  $\geq$  18 years) septic patients with moderate non-bleeding anemia (hemoglobin  $\leq$  10 g/dL) within 24 hours after admission to the intensive care unit (ICU) between 2001 and 2012. After data preprocessing, partitioning around medoids function was used for unsupervised cluster analysis. We used Kaplan-Meier survival analysis and multivariable Cox proportional hazard models to explore the relationship between RBC transfusion and mortality.

Results: In total, 6,821 septic patients with moderate non-bleeding anemia within 24 hours after ICU admission, and 3,874 patients (56.8%) received RBC transfusion during their stay in the ICU. Using unsupervised cluster analysis, we identified three phenotypes of septic patients with moderate non-bleeding anemia: cluster A (n = 1,835) was characterized by advanced age and heart issues; cluster B (n = 3,043) was characterized by mild disease and relatively high hemoglobin levels; and cluster C (n = 1,943) was characterized by severe disease, low mean arterial pressure, bloodstream infection, coagulopathy, high lactate levels, and high mortality. Only for patients in cluster C, RBC transfusion exhibited protective effects in terms of the 14-day [hazard ratio (HR), 0.50; 95% confidence interval (CI), 0.41 - 0.61; p < 0.001], 28-day (HR, 0.61; 95% CI, 0.51 - 0.72; p < 0.001), and 90-day (HR, 0.67; 95% CI, 0.58 - 0.78; p < 0.001) mortality after adjusting the confounding variables.

Conclusions: Utilizing unsupervised cluster analysis, we identified three phenotypes of septic patients with moderate non-bleeding anemia who had different responses to RBC transfusion. In the future, randomized controlled trials about prognostic outcomes of RBC transfusions can focus on the specific phenotype of sepsis.

(Clin. Lab. 2022;68;xx-xx, DOI: 10.7754/Clin.Lab.2021.210619)

#### **Correspondence:**

Xianyao Wan Department of Intensive Care Unit The First Affiliated Hospital of Dalian Medical University Zhongshan Road No. 222 Dalian City, 116023 Liaoning Province

China

Phone: +86 411-83635963

Email: wanxianyaocn@hotmail.com

Manuscript accepted September 2, 2021

Manuscript accepted September 2, 2021

## **Supplementary Tables and Figures**

Table S1. Characteristics of patients who received or did not receive a red blood cell transfusion.

Characteristic	Overall n = 6,821	Transfusion n = 3,874	No transfusion n = 2,947	<b>p</b> *			
Age (y), median (IQR)	69.15 (56.60 - 80.11) 68.66 (56.20 - 79.31)		69.83 (57.10 - 81.14)	< 0.001			
Male, No. (%)	3,439 (50.4%)	2,030 (52.4%)	1,409 (47.8%)	< 0.001			
Type of ICU, No. (%)				< 0.001			
CCU	751 (11.0%)	448 (11.6%)	303 (10.3%)				
CSRU	1,149 (16.8%)	819 (21.1%)	330 (11.2%)				
MICU	3,350 (49.1%)	1,618 (41.8%)	1,732 (58.8%)				
SICU	991 (14.6%)	611 (15.7%)	380 (12.8%)				
TSICU	580 (8.5%)	378 (9.8%)	202 (6.9%)				
HR (/min), median (IQR) a	87.12 (76.87 - 98.39)	88.48 (78.45 - 99.46)	85.34 (75.07 - 96.63)	< 0.001			
MAP (mmHg), median (IQR) <sup>a</sup>	73.75 (67.91 - 80.70)	73.90 (68.20 - 80.75)	73.56 (67.38 - 80.69)	0.059			
RR (/min), median (IQR) a	18.98 (16.46 - 22.21)	18.71 (16.17 - 22.08)	19.33 (16.94 - 22.32)	< 0.001			
SpO <sub>2</sub> (%), median (IQR) <sup>a</sup>	97.57 (96.21 - 98.72)	97.83 (96.44 - 98.90)	97.24 (95.92 - 98.42)	< 0.001			
SOFA, median (IQR)	5.00 (4.00 - 8.00)	6.00 (4.00 - 8.00)	5.00 (3.00 - 7.00)	< 0.001			
LODS, median (IQR)	5.00 (3.00 - 7.00)	6.00 (4.00 - 8.00)	4.00 (3.00 - 6.00)	< 0.001			
SAPS II, median (IQR)	41.00 (33.00 - 51.00)	43.00 (34.00 - 53.00)	39.00 (31.00 - 48.00)	< 0.001			
	Comorb	idity, No. (%)					
Cerebrovascular disease	514 (7.5%)	303 (7.8%)	211 (7.2%)	0.328			
Intracranial injury	191 (2.8%)	121 (3.1%)	70 (2.4%)	0.075			
Cardiac disease	2,808 (41.2%)	1,690 (43.6%)	1,118 (37.9%)	< 0.001			
Chronic kidney disease	1,385 (20.3%)	689 (17.8%)	696 (23.6%)	< 0.001			
COPD/Asthma	1,365 (20.0%)	702 (18.1%)	663 (22.5%)	< 0.001			
Liver disease	1,055 (15.5%)	717 (18.5%)	338 (11.5%)	< 0.001			
Hematological disease	618 (9.1%)	387 (10.0%)	231 (7.8%)	0.002			
Solid organ malignancies	1,010 (14.8%)	519 (13.4%)	491 (16.7%)	< 0.001			
Organ transplant	132 (1.9%)	70 (1.8%)	62 (2.1%)	0.428			
Peptic ulcer	159 (2.3%)	119 (3.1%)	39 (1.3%)	< 0.001			
	Laboratory findings						
APTT (s), median (IQR) b	37.20 (29.90 - 52.50)	38.90 (31.00 - 56.58)	35.00 (28.80 - 47.90)	< 0.001			
PT (s), median (IQR) b	15.70 (14.00 - 18.50)	15.90 (14.20 - 18.70)	15.40 (13.70 - 18.20)	< 0.001			
INR, median (IQR) b	1.50 (1.20 - 1.90)	1.50 (1.30 - 1.90)	1.40 (1.20 - 1.80)	< 0.001			
Creatinine (mg/dL), median (IQR) <sup>b</sup>	1.30 (0.90 - 2.10)	1.30 (0.90 - 2.10)	1.30 (0.90 - 2.10)	0.788			
Hematocrit (%), median (IQR) <sup>c</sup>	26.00 (23.20 - 28.00)	24.50 (22.00 - 26.87)	27.60 (25.80 - 29.00)	< 0.001			
Hemoglobin (g/dL), median (IQR) <sup>c</sup>	8.70 (7.80 - 9.40)	8.30 (7.40 - 9.10)	9.20 (8.50 - 9.60)	< 0.001			
Lactate (mmol/L), median (IQR) <sup>b</sup>	2.48 (1.71 - 3.67)	2.80 (1.90 - 4.20)	2.20 (1.51 - 3.00)	< 0.001			
Platelets (10 <sup>9</sup> /L), median (IQR) <sup>c</sup>	166.00 (102.00 - 252.00)	143.00 (85.00 - 227.75)	192.00 (128.00 - 280.50)	< 0.001			
WBC (10 <sup>9</sup> /L), median (IQR) <sup>b</sup>	13.00 (8.80 - 18.30)	13.50 (9.10 - 18.80)	12.40 (8.30 - 17.60)	< 0.001			

Table S1. Characteristics of patients who received or did not receive a red blood cell transfusion (continued).

Characteristic	Overall n = 6,821	Transfusion n = 3,874	No transfusion n = 2,947	p*		
Site of infection, No. (%)						
Respiratory tract	3,189 (46.8%)	1,832 (47.3%)	1,357 (46.0%)	0.320		
Abdomen	1,851 (27.2%)	1,090 (28.1%)	761 (25.8%)	0.036		
Urogenital tract	2,064 (30.2%)	1,128 (29.1%)	936 (31.8%)	0.020		
Skin/Soft tissue	630 (9.2%)	369 (9.5%)	261 (8.9%)	0.367		
Bloodstream	2,578 (37.8%)	1,520 (39.2%)	1,058 (35.9%)	0.005		
Other d	1,302 (19.1%)	804 (20.8%)	498 (16.9%)	< 0.001		
Site of operation, No. (%)						
Brain	178 (2.6%)	124 (3.2%)	54 (1.8%)	< 0.001		
Lung	1,561 (22.8%)	1,115 (28.8%)	446 (15.1%)	< 0.001		
Heart	1,452 (21.3%)	1,023 (26.4%)	429 (14.6%)	< 0.001		
Great vessels	378 (5.6%)	326 (8.4%)	52 (1.8%)	< 0.001		
Abdomen	2,351 (34.5%)	1,608 (41.5%)	743 (25.2%)	< 0.001		
Bones/Joints	576 (8.4%)	405 (10.5%)	171 (5.8%)	< 0.001		
Mechanical ventilation, No. (%)	3,738 (54.8%)	2,548 (65.8%)	1,190 (40.4%)	< 0.001		
Renal replacement therapy, No. (%)	412 (6.0%)	246 (6.4%)	166 (5.6%)	0.238		
Outcomes						
14 - day mortality, No. (%)	1,015 (14.8%)	521 (13.4%)	494 (16.8%)	< 0.001		
28 - day mortality, No. (%)	1,468 (21.5%)	825 (21.3%)	643 (21.8%)	0.624		
90 - day mortality, No. (%)	90 - day mortality, No. (%) 2,121 (31.1%)		882 (29.9%)	0.074		
ICU LOS, median (IQR)	CU LOS, median (IQR) 4.00 (2.00 - 8.00)		3.00 (2.00 - 4.00)	< 0.001		
Hospital LOS, median (IQR)	11.00 (7.00 - 20.00)	14.00 (9.00 - 24.00)	9.00 (5.00 - 14.00)	< 0.001		

Abbreviations: IQR - interquartile range, ICU - intensive care unit, CCU - coronary care unit, CSRU - cardiac surgery recovery unit, MICU - medical intensive care unit, SICU - surgical intensive care unit, TSICU - trauma/surgical intensive care unit, HR - heart rate, MAP - mean arterial pressure, RR - respiratory rate, SpO $_2$  - pulse oxygen saturation, SOFA - sequential organ failure assessment, LODS - logistic organ dysfunction score, SAPS II - simplified acute physiology score II, COPD - chronic obstructive pulmonary disease, APTT - activated partial throm-boplastin time, PT - prothrombin time, INR - international normalized ratio, WBC - white blood cell, LOS - length of stay.

Clin. Lab. 5/2022 3

<sup>\*</sup>p - between transfusion and no transfusion.

<sup>&</sup>lt;sup>a</sup> - The mean value within 24 hours of ICU admission was calculated.

<sup>&</sup>lt;sup>b</sup> - The maximum value within 24 hours of ICU admission was calculated.

<sup>&</sup>lt;sup>c</sup> - The minimum value within 24 hours of ICU admission was calculated.

 $<sup>^{</sup>m d}$  - The other sites of infection included central nervous system, bones, and unspecified site.

Table S2. Characteristics of patients between clusters.

Cluster A Cluster B Cluster C *						
Characteristic	n = 1,835	n = 3,043	n = 1,943	p*		
Age (y), median (IQR)	71.50 (60.55 - 80.03)	68.32 (55.54 - 80.38)	67.83 (54.94 - 79.90)	< 0.001		
Male, No. (%)	928 (50.6%)	1,435 (47.2%)	1,076 (55.4%)	< 0.001		
Type of ICU, No. (%)				< 0.001		
CCU	287 (15.6%)	339 (11.1%)	125 (6.4%)			
CSRU	872 (47.5%)	147 (4.8%)	130 (6.7%)			
MICU	419 (22.8%)	1,808 (59.4%)	1,123 (57.8%)			
SICU	156 (8.6%)	461 (15.2%)	374 (19.3%)			
TSICU	101 (5.5%)	288 (9.5%)	288 (9.5%) 191 (9.8%)			
HR (/minute), median (IQR) a	85.97 (78.14 - 94.16)	84.57 (74.15 - 95.96)	93.04 (81.17 - 105.79)	< 0.001		
MAP (mmHg), median (IQR) <sup>a</sup>	74.57 (69.80 - 80.12)	74.64 (68.18 - 82.35)	71.28 (65.81 - 78.54)	< 0.001		
RR (/minute), median (IQR) a	17.90 (15.80 - 20.38)	18.92 (16.65 - 22.00)	20.27 (17.34 - 23.95)	< 0.001		
SpO <sub>2</sub> (%), median (IQR) <sup>a</sup>	98.24 (97.09 - 99.09)	97.08 (95.86 - 98.21)	97.71 (96.07 - 98.94)	< 0.001		
SOFA, median (IQR)	5.00 (4.00 - 7.00)	4.00 (3.00 - 5.00)	8.00 (6.00 - 11.00)	< 0.001		
LODS, median (IQR) 5.00 (4.00 - 7.00)		4.00 (2.00 - 5.00)	8.00 (6.00 - 10.00)	< 0.001		
SAPS II, median (IQR)	41.00 (34.00 - 49.00)	35.00 (29.00 - 42.00)	53.00 (44.00 - 63.00)	< 0.001		
	Comorbid	ity, No. (%)				
Cerebrovascular disease	168 (9.2%)	227 (7.5%)	119 (6.1%)	0.002		
Intracranial injury	36 (2.0%)	105 (3.5%)	50 (2.6%)	0.007		
Cardiac disease	1,337 (72.9%)	896 (29.4%)	575 (29.6%)	< 0.001		
Chronic kidney disease	331 (18.0%)	632 (20.8%)	422 (21.7%)	0.013		
COPD/Asthma	408 (22.2%)	660 (21.7%)	297 (15.3%)	< 0.001		
Liver disease	113 (6.2%)	370 (12.2%)	572 (29.4%)	< 0.001		
Hematological disease	110 (6.0%)	290 (9.5%)	218 (11.2%)	< 0.001		
Solid organ malignancies	131 (7.1%)	551 (18.1%)	328 (16.9%)	< 0.001		
Organ transplant	39 (2.1%)	60 (2.0%)	33 (1.7%)	0.623		
Peptic ulcer	23 (1.3%)	70 (2.3%)	65 (3.3%)	< 0.001		
	Laborato	ry findings				
APTT (s), median (IQR) b	39.30 (31.50 - 56.13)	33.40 (28.20 - 45.25)	41.70 (32.65 - 61.25)	< 0.001		
PT (s), median (IQR) b	15.40 (14.10 - 17.10)	15.00 (13.60 - 17.65)	17.40 (15.00 - 21.90)	< 0.001		
INR, median (IQR) b	1.40 (1.30 - 1.70)	1.40 (1.20 - 1.71)	1.70 (1.40 - 2.40)	< 0.001		
Creatinine (mg/dL), median (IQR) <sup>b</sup>	1.10 (0.80 - 1.60)	1.20 (0.80 - 1.80)	1.90 (1.20 - 3.15)	< 0.001		
Hematocrit (%), median (IQR) <sup>c</sup>	24.00 (21.10 - 26.60)	27.30 (25.10 - 28.80)	25.40 (23.00 - 27.60)	< 0.001		
Hemoglobin (g/dL), median (IQR) <sup>c</sup>	8.10 (7.20 - 9.00)	9.10 (8.50 - 9.60)	8.50 (7.75 - 9.20)	< 0.001		
Lactate (mmol/L), median (IQR) <sup>b</sup>	2.70 (1.90 - 3.60)	2.10 (1.50 - 2.70)	3.54 (2.30 - 5.90)	< 0.001		
Platelets (10 <sup>9</sup> /L), median (IQR) <sup>c</sup>	151.00 (107.00 - 214.00)	199.00 (128.00 - 288.00)	125.00 (67.00 - 220.00)	< 0.001		
WBC (10 <sup>9</sup> /L), median (IQR) <sup>b</sup>	13.80 (10.40 - 17.90)	11.10 (7.60 - 15.90)	15.70 (9.60 - 22.50)	< 0.001		
Site of infection, No. (%)						
Respiratory tract	806 (43.9%)	1,469 (48.3%)	914 (47.0%)	0.012		
Abdomen	283 (15.4%)	793 (26.1%)	775 (39.9%)	< 0.001		
Urogenital tract	612 (33.4%)	970 (31.9%)	482 (24.8%)	< 0.001		

Table S2. Characteristics of patients between clusters (continued).

Characteristic	Cluster A n = 1,835	Cluster B n = 3,043	Cluster C n = 1,943	<b>p</b> *			
Skin/Soft tissue	194 (10.6%)	283 (9.3%)	153 (7.9%)	0.016			
Bloodstream	321 (17.5%)	852 (28.0%)	1,405 (72.3%)	< 0.001			
Other <sup>d</sup>	396 (21.6%)	520 (17.1%)	386 (19.9%)	< 0.001			
	Site of operation, No. (%)						
Brain	43 (2.3%)	93 (3.1%)	42 (2.2%)	0.109			
Lung	472 (25.7%)	551 (18.1%)	538 (27.7%)	< 0.001			
Heart	1,172 (63.9%)	194 (6.4%)	86 (4.4%)	< 0.001			
Great vessels	148 (8.1%)	102 (3.4%)	128 (6.6%)	< 0.001			
Abdomen	293 (16.0%)	859 (28.2%)	1,199 (61.7%)	< 0.001			
Bones/Joints	140 (7.6%)	270 (8.9%)	166 (8.5%)	0.313			
Mechanical ventilation, No. (%)	1,616 (88.1%)	709 (23.3%)	1,413 (72.7%)	< 0.001			
Renal replacement therapy, No. (%)	65 (3.5%)	135 (4.4%)	212 (10.9%)	< 0.001			
Outcomes							
14 - day mortality, No. (%)	172 (9.4%)	308 (10.1%)	535 (27.5%)	< 0.001			
28 - day mortality, No. (%)	260 (14.2%)	474 (15.6%)	734 (37.8%)	< 0.001			
90 - day mortality, No. (%)	392 (21.4%)	757 (24.9%)	972 (50.0%)	< 0.001			
ICU LOS, median (IQR)	5.00 (3.00 - 9.00)	3.00 (2.00 - 5.00)	6.00 (3.00 - 12.00)	< 0.001			
Hospital LOS, median (IQR)	13.00 (9.00 - 19.00)	10.00 (6.00 - 16.00)	14.00 (7.00 - 26.00)	< 0.001			

Abbreviations: IQR - interquartile range, ICU - intensive care unit, CCU - coronary care unit, CSRU - cardiac surgery recovery unit, MICU medical intensive care unit, SICU - surgical intensive care unit, TSICU - trauma/surgical intensive care unit, HR - heart rate, MAP - mean arterial pressure, RR - respiratory rate, SpO<sub>2</sub> - pulse oxygen saturation, SOFA: sequential organ failure assessment, LODS - logistic organ dysfunction score, SAPS II - simplified acute physiology score II, COPD - chronic obstructive pulmonary disease, APTT - activated partial thromboplastin time, PT - prothrombin time, INR - international normalized ratio, WBC - white blood cell, LOS - length of stay.

Table S3. Multivariate adjusted hazard ratio of death due to red blood cell transfusion at 14 - day, 28 - day, and 90 - day intervals.

	14 - day mortality		28 - day mortality		90 - day mortality	
	Hazard ratio (95% CI)	p	Hazard ratio (95% CI)	p	Hazard ratio (95% CI)	р
Overall	0.67 (0.58 - 0.78)	< 0.001	0.82 (0.73 - 0.93)	0.002	0.92 (0.83 - 1.02)	0.119
Cluster A	0.83 (0.58 - 1.18)	0.302	0.99 (0.73 - 1.33)	0.937	1.01 (0.79 - 1.30)	0.931
Cluster B	0.93 (0.72 - 1.21)	0.596	1.02 (0.83 - 1.25)	0.877	1.12 (0.96 - 1.32)	0.153
Cluster C	0.50 (0.41 - 0.61)	< 0.001	0.61 (0.51 - 0.72)	< 0.001	0.67 (0.58 - 0.78)	< 0.001

Abbreviations: CI - confidence interval.

<sup>\*</sup>p - between clusters.

a - The mean value within 24 hours of ICU admission was calculated.

<sup>&</sup>lt;sup>b</sup> - The maximum value within 24 hours of ICU admission was calculated.

<sup>&</sup>lt;sup>c</sup> - The minimum value within 24 hours of ICU admission was calculated.

 $<sup>^{\</sup>rm d}$  - The other sites of infection included central nervous system, bones, and unspecified site.




Figure S1. Percent of missing values for variables extracted for MIMIC III database (range: 0 - 1).

a: Comorbidity, b: Site of infection, c: Site of operation.

Abbreviations: ICU - intensive care unit, SOFA - Sequential Organ Failure Assessment, LODS - Logistic organ dysfunction score, SAPS II - Simplified acute physiology score II, COPD - Chronic obstructive pulmonary disease, APTT - Activated partial thromboplastin time, PT - Prothrombin time, INR - international normalized ratio, WBC - White blood cell.




Figure S2. The importance of variables related to red blood cell transfusion according to Boruta algorithm.

Note: Blue boxplots represent the minimal, mean, and maximum Z score (importance) of shadow variables which are created by shuffling original ones. The Boruta algorithm compares the Z score between real variables and shadow variables. Variables that have significant lower Z score than their shadow ones are classified as unimportant variables which are represented by red boxplots. Yellow and green boxplots represent probably and definitely important variables which have higher Z score than their shadow ones.




Figure S3. Spearman's coefficient between variables.




Figure S4. Silhouette coefficient plot.

Note: High silhouette coefficient reflects the rationality of individuals being grouped into their own cluster rather than others.

Clin. Lab. 5/2022 7